Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Concizumab Prophylaxis in Haemophilia A or B Without Inhibitors
NCT04082429Phase 3Active, not recruiting
- Sponsor
- Novo Nordisk
- Start
- Nov 2019
- Primary completion
- Jul 2022
- Modality
- Monoclonal Antibodies
- Countries
- 33
01
Overview
Phase 3, randomised, open-label trial of concizumab in hemophilia A and Hemophilia B (HB) (4 arms), sponsored by Novo Nordisk. Primary endpoint: Rate of Treated Spontaneous and Traumatic Bleeding Episodes at 56 weeks. Started Nov 2019; status: active, not recruiting.
02
Drugs
concizumab
03
Conditions
hemophilia AHemophilia B (HB)
Beyond the preview
Go deeper on NCT04082429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04082429.